Chester County News and Community Website
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) reported that its liver disease drug Rezdiffra improved measures of liver damage across patients carrying common genetic risk variants for metabolic dysfunction-associated …
Madrigal Study Finds Rezdiffra Benefits Across Genetic Risks Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (Nasdaq: MDGL) granted stock options and restricted stock units to 27 newly hired non-executive employees in September, using equity incentives to support hiring as …
Madrigal Grants Equity Awards to 27 New Employees Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (Nasdaq: MDGL) will present at the Cantor Global Healthcare Conference on Sept. 10, putting the commercial and clinical strategy around its MASH treatment Rezdiffra …
Madrigal to Put MASH Drug Strategy Before Investors at Cantor Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) recently granted 4,676 restricted stock units to 13 newly hired non-executive employees on Aug. 15 as employment inducements, extending equity compensation to …
Madrigal Grants Stock Awards to 13 New Employees Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) appointed Johnson & Johnson research executive John C. Reed, M.D., Ph.D., to its board of directors as the biopharmaceutical company builds on …
Madrigal Adds J&J R&D Chief to Board as MASH Push Expands Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (Nasdaq: MDGL) granted 4,263 restricted stock units to 10 newly hired non-executive employees on Aug. 1, using equity compensation as an employment inducement as …
Madrigal Uses Equity Awards to Recruit 10 Employees Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (Nasdaq: MDGL) will present Tuesday, Aug. 11, at the Canaccord Genuity 46th Annual Growth Conference, giving investors an opportunity to hear from the company …
Madrigal Sets Investor Presentation as MASH Strategy Advances Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (Nasdaq: MDGL) reported a 71% increase in second-quarter revenue as adoption of its liver-disease drug Rezdiffra expanded, though higher commercial and research spending widened …
Madrigal Sales Jump 71% as Rezdiffra Adoption Expands Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals (NASDAQ: MDGL) granted stock options and restricted stock units to 10 newly hired employees under its inducement equity plan, using stock-based compensation to support recruitment …
Madrigal Grants Equity Awards to 10 New Employees Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals (Nasdaq: MDGL) will report its second-quarter 2026 financial results on July 30 before U.S. markets open, giving investors an updated view of the commercial performance …
Madrigal Pharmaceuticals Sets July 30 Earnings Release as Investors Await MASH Update Read More